Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards.
The importance of spontaneously developing collateral vessels to supplement perfusion of tissue rendered ischemic by vascular obstruction was recognized many years ago. However, it was not until potent angiogenesis factors were identified, purified, and produced in sufficient quantities, that the field began its rapid development. In the early 1990s it was first shown that basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) proteins could actually stimulate collateral flow. However, additional studies also demonstrated that the duration of exposure of the vessels to angiogenesis factors was critical, and that the administration of proteins, with their relatively brief half-lives, may pose important practical limitations. The demonstration that gene therapy can improve collateral function presents one of the solutions to the conundrum, since gene therapy can be considered a sophisticated form of a sustained delivery system. The results of several clinical trials have been reported. All involve administration of single angiogenesis agents, and most are Phase I trials. The two studies rising to Phase II status demonstrated no treatment effect on the primary end-point. It may therefore be relevant to consider that the molecular mechanisms responsible for angiogenesis are extraordinarily complex, and an optimal angiogenesis intervention may require a 'multiple factor' strategy. It is important to note that no serious side-effects ascribable to an angiogenesis agent were recognized in these trials. However, angiogenesis agents are potent molecules with multiple activities. It is therefore possible that they might occasionally cause side-effects, some serious. Among these, based on their biologic activities, are neovascularization of non-targeted tissues, expansion and induction of instability of atherogenic plaque, and growth of tumors. In summary, there is ample experimental evidence justifying an optimistic outlook relating to our eventually being successful in enhancing collateral flow to ischemic tissue in a clinical setting. However, we are not there yet, and identification of the optimal angiogenesis strategy is still unclear. Additional experimental work, in parallel with large, carefully controlled clinical trials are needed to continue the exciting advances of the last decade, and to achieve the goal of providing patients with alternative potent therapies to improve collateral flow, and thereby to alleviate their symptoms and perhaps to prolong their lives.
Epstein
S E
SE
Cardiovascular Research Institute of the MedStar Research Institute, Washington Hospital Center, Washington, DC, USA.sxe2@mhg.edu
Fuchs
S
S
Zhou
Y F
YF
Baffour
R
R
Kornowski
R
R
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D003097:Collateral Circulation; D003326:Coronary Circulation; D003327:Coronary Disease / Q000628:therapy*; D004195:Disease Models, Animal; D004285:Dogs; D016228:Endothelial Growth Factors / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D015870:Gene Expression; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D005822:Genetic Vectors / Q000009:adverse effects; D006133:Growth Substances / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D007022:Hypotension / Q000139:chemically induced; D008222:Lymphokines / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D018919:Neovascularization, Physiologic; D016032:Randomized Controlled Trials as Topic; D013314:Stress, Mechanical; D019076:Transgenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D006133:Growth Substances; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2